<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138777">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01294397</url>
  </required_header>
  <id_info>
    <org_study_id>20101324</org_study_id>
    <nct_id>NCT01294397</nct_id>
  </id_info>
  <brief_title>Effects of Denosumab on the Pharmacokinetics of Etanercept</brief_title>
  <official_title>The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Bone Mineral Density and Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, single sequence, denosumab single-dose study in
      postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis (RA) being
      treated with etanercept.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was stopped because only 38% of subjects had been enrolled after 5 years and
    multiple protocol amendments aimed at improving enrollment.
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) from 0 to 168 hours for etanercept.</measure>
    <time_frame>A period of 21 days following denosumab administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax) for etanercept.</measure>
    <time_frame>A period of 21 days following denosumab administration.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum serum concentration (tmax) for etanercept.</measure>
    <time_frame>A period of 21 days following denosumab administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum denosumab concentration.</measure>
    <time_frame>At 14 and 21 days following denosumab administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-telopeptide (sCTx) concentrations.</measure>
    <time_frame>A period of 168 days following denosumab administration.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Postmenopausal</condition>
  <condition>Osteopenia</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All 44 subjects will receive denosumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All 44 subjects will receive etanercept.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>All 44 subjects will continue to receive a 50-mg dose of etanercept once weekly.</description>
    <arm_group_label>Denosumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>All 44 subjects will receive a single 60-mg dose of denosumab.</description>
    <arm_group_label>Etanercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women (postmenopausal is defined as no vaginal bleeding or spotting
             for at least 12 months)

          -  Low bone mineral density (BMD) as determined by screening BMD T-scores of the lumbar
             spine (L1 to L4), or total evaluable vertebrae (if fewer than L1 to L4), or total hip
             ≤ -1.0

          -  Receiving a 50-mg dose of etanercept once weekly ≥ 6 months prior to screening and
             expected to continue etanercept treatment at this dose and frequency through EOS

          -  If currently taking methotrexate (MTX), receiving a stable dose (7.5 to 20 mg/week)
             of MTX ≥ 8 weeks prior to screening

          -  Willing and able to take ≥ 1,000 mg elemental calcium and ≥ 400 IU vitamin D daily
             upon enrollment

        Exclusion Criteria:

          -  Type 1 diabetes; OR poorly controlled Type 2 diabetes (hemoglobin A1c (HbA1c) &gt; 8.0%
             at screening; HbA1c ≤ 8.0% within 6 months of screening is acceptable if supporting
             laboratory documentation is available)

          -  History of heart failure, coronary artery bypass graft, or cardiac arrhythmia; OR
             history of acute coronary syndrome

          -  Comorbid autoimmune disease, demyelinating disease, or hematologic abnormalities

          -  History of joint replacement in hand and/or wrist; OR history of fused joint in hand
             and/or wrist

          -  Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw; OR
             active dental or jaw condition that requires oral surgery, or non-healed dental/oral
             surgery; OR planned invasive dental procedure(s) during the course of the study

          -  Previous exposure to denosumab
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 8, 2016</lastchanged_date>
  <firstreceived_date>January 13, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amgen</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Osteopenia</keyword>
  <keyword>Rheumatoid</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
